Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group

Villablanca, Judith G; London, Wendy B; Naranjo, Arlene; McGrady, Patrick; Ames, Matthew M; Reid, Joel M; McGovern, Renee M; Buhrow, Sarah A; Jackson, Hollie; Stranzinger, Enno; Kitchen, Brenda J; Sondel, Paul M; Parisi, Marguerite T; Shulkin, Barry; Yanik, Gregory A; Cohn, Susan L; Reynolds, C Patrick (2011). Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clinical cancer research, 17(21), pp. 6858-66. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-11-0995

Full text not available from this repository. (Request a copy)

To determine the response rate to oral capsular fenretinide in children with recurrent or biopsy proven refractory high-risk neuroblastoma.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Institute of Diagnostic, Interventional and Paediatric Radiology

UniBE Contributor:

Stranzinger, Enno

ISSN:

1078-0432

Publisher:

American Association for Cancer Research

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:22

Last Modified:

11 Jul 2018 17:10

Publisher DOI:

10.1158/1078-0432.CCR-11-0995

PubMed ID:

21908574

Web of Science ID:

000296624000029

URI:

https://boris.unibe.ch/id/eprint/7665 (FactScience: 212977)

Actions (login required)

Edit item Edit item
Provide Feedback